Merck

Last updated January 31, 2026

124

Innovation Areas

5,362

Inventors

Collaborations

Substituted amino-pyrimidine cgrp-active compounds: MerckRecent Research Landscape

Uncontrolled lymphocyte proliferation in multiple sclerosis leads to irreversible neurological damage, which is mitigated through precise titration of substituted amino-pyrimidine compounds. These specific chemical scaffolds allow for targeted immune modulation while minimizing systemic toxicity risks.

What technical problems is Merck addressing in Substituted amino-pyrimidine cgrp-active compounds?

Progressive neurodegeneration and autoimmune relapse

(6)evidences

Standard therapies fail to stop the accumulation of disability in advanced multiple sclerosis. Addressing this prevents irreversible neurological decline and clinical relapse.

Acute migraine symptom persistence

(2)evidences

Severe cranial vascular inflammation and sensory hypersensitivity. Mitigating these symptoms restores patient functionality and reduces neurological distress.